General Information of Drug Combination (ID: DC8ESGK)

Drug Combination Name
Propylthiouracil Perphenazine
Indication
Disease Entry Status REF
Ischemic Stroke, Acute Phase 2 [1]
Component Drugs Propylthiouracil   DM6D7N8 Perphenazine   DMA4MRX
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Propylthiouracil
Disease Entry ICD 11 Status REF
Hyperthyroidism 5A02 Approved [2]
Thyroid crisis N.A. Approved [3]
Propylthiouracil Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Iodothyronine deiodinase type I (DIO1) TTU3X26 IOD1_HUMAN Inhibitor [7]
Thyroid peroxidase (TPO) TT52XDZ PERT_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------
Propylthiouracil Interacts with 12 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Taste receptor type 2 member 38 (TAS2R38) OTX5MM36 T2R38_HUMAN Increases Activity [9]
T-box transcription factor TBX3 (TBX3) OTM64N7K TBX3_HUMAN Increases Expression [6]
Thyroglobulin (TG) OT3ELHIJ THYG_HUMAN Decreases Expression [10]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [6]
Integrin beta-5 (ITGB5) OT21MF51 ITB5_HUMAN Decreases Expression [6]
Low-density lipoprotein receptor-related protein 2 (LRP2) OTZ6W681 LRP2_HUMAN Decreases Expression [10]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Increases Activity [11]
DNA-binding protein inhibitor ID-3 (ID3) OTUULW5Z ID3_HUMAN Increases Expression [6]
Krueppel-like factor 9 (KLF9) OTBFEJRQ KLF9_HUMAN Increases Expression [6]
Carbonic anhydrase 6 (CA6) OTIX56CJ CAH6_HUMAN Affects Response To Substance [12]
Mitochondrial substrate carrier family protein ancA (ancA?) OTTU3FKC ADT_DICDI Increases ADR [13]
Basic salivary proline-rich protein 1 (PRB1) OTV0SYMD PRP1_HUMAN Affects Response To Substance [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 DOT(s)
Indication(s) of Perphenazine
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [4]
Mixed anxiety and depressive disorder N.A. Investigative [5]
Perphenazine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Antagonist [14]
------------------------------------------------------------------------------------
Perphenazine Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [15]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [16]
------------------------------------------------------------------------------------
Perphenazine Interacts with 7 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [17]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [18]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [19]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Metabolism [17]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [17]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [17]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DME(s)
Perphenazine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Troponin I, cardiac muscle (TNNI3) OT65E12V TNNI3_HUMAN Increases Expression [20]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05762146) Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6650).
3 Propylthiouracil FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 209).
5 Perphenazine FDA Label
6 Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
7 Type 1 iodothyronine deiodinase is the major source of circulating T3 in hyperthyroidism: implications for therapy. Nat Clin Pract Endocrinol Metab. 2007 Nov;3(11):740-1.
8 Bioinorganic chemistry in thyroid gland: effect of antithyroid drugs on peroxidase-catalyzed oxidation and iodination reactions. Bioinorg Chem Appl. 2006:23214.
9 Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin. PLoS One. 2011;6(5):e20123.
10 Thyroid organotypic rat and human cultures used to investigate drug effects on thyroid function, hormone synthesis and release pathways. Toxicol Appl Pharmacol. 2012 Apr 1;260(1):81-8. doi: 10.1016/j.taap.2012.01.029. Epub 2012 Feb 8.
11 A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
12 Responsiveness to 6-n-propylthiouracil (PROP) is associated with salivary levels of two specific basic proline-rich proteins in humans. PLoS One. 2012;7(2):e30962. doi: 10.1371/journal.pone.0030962. Epub 2012 Feb 1.
13 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
14 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
15 Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
16 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
17 Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
18 Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84.
19 Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
20 An unexpected increase of troponin I after perphenazine depot injection. Ann Pharmacother. 2004 Feb;38(2):353-4. doi: 10.1345/aph.1D234. Epub 2003 Dec 23.